-Assess the state of the business-Recommend changes needed to prepare the company for a capital raise or sale of the business-I restructured the company to preserve cash and increased profitability within 45 days-Consolidated and restructured debt terms to free up some additional working capital-Remain an Advisor to the CEO in ongoing discussions with financial institutions and M&A

Led successful turnaround of declining construction services business, increasing annual revenue by 33% in one year and achieving profitability.• Talent Management: Reduced headcount by 50%, upgraded management team, promoted and coached top talent, adding strategic in-house personnel with valued supervisory and trade skills. Avoided all search and consulting fees.• Turnaround/Restructuring: Vertically integrated operations to enable company to competitively bid work in new geographies, which allowed VCS to bid on and win projects across the U.S.• Cost-Saving Measures: Improved timeliness and quality of project bidding, and execution while reducing SG&A by $1 million.• Business Development: Restructure enabled strategic transactions with an upside potential of $30 million in revenue and $10 million in net income, including an exclusive national gym chain contract for 4 initial projects in Tennessee.• Financial Management: Developed comprehensive financial projections to support business development efforts and improve timeliness and relevance of financial reports. Reduced working capital requirements and streamlined AR/AP procedures by 15%.• Performance Management: Facilitated ongoing and periodic meetings with all division employees to review and discuss project-level and consolidated financial performance.

Resolved significant obstacles to growth – sourcing top talent, cutting costs, navigating critical compliance issues and focusing on top-profit offerings at private US specialty pharmacy provider serving bleeding disorder patients. Drove changes and rebranding strategies designed to improve EBIDTA, cost, and core business, including 270%, 7-year expected rise in net income.Reorganized core functions and staff for optimum profit, efficiency, and market opportunities after recruitment to prepare company for sale. Leveraged business acumen to identify talent, cash sources, and strategies to remediate issues and stabilize operations. Met with Board to address changes crucial to regulatory mandates and growing revenue (eliminating 5 of 6 business lines); arranged for lines of credit and capital. Secured expert legal and general counsel to navigate grave government actions. Oversaw IT operations procurement and systems migration to HIPAA-compliant co-location and services host. Forged trust for changes needed in new corporate culture; strengthened employee code of conduct and compliance via training initiatives.

Drove efficiencies, accessed new market segments, expanded market opportunities via domestic and ex-US licensing and partnerships, created revenue gains, and identified and evaluated business development opportunities. Created gains across Mylan Specialty’s Rx portfolio, including EpiPen, Perforomist, and Emsam in the face of stiff competition. Led 58% YoY revenues, achieving blockbuster status for EpiPen 25 years post-launch.Drove 50% YoY revenue gains for EpiPen. Refined physician targeting, evolved physician detail effort to maximize value and increase volume of prescriptions. Initiated a strategic PR program, EpiPen4Schools, which increased awareness and drove demand for EpiPen, with EpiPen being stocked at 60,000 schools nationwide. Held P&L authority, overseeing 12 direct and 500 indirect exports across finance, regulatory, legal, medical affairs, HR, marketing, public relations, managed markets, government affairs, business development, and sales.• Promotional Leadership: Doubled EpiPen sales in single year through integrated multi-channel marketing and PR campaigns/managed markets, government, and trade initiatives. Forged new strategy to reach public schools resulting in 60,000+ schools stocking EpiPen to treat first-time anaphylaxis in school settings, driving brand loyalty and sales success.• Global Product Licensing: Negotiated Pfizer licensing contract to market EpiPen in Japan; set ex-US strategy for additional markets.• Investor Relations: Among five Mylan executives who presented at investor day (sole Mylan Specialty presenter); leveraged previous analyst relationships and capital markets expertise to engage institutional investors.

Leveraged expertise to create an award-winning launch for Moxatag, the first FDA-approved once-daily amoxicillin. Commercialized Moxatag in <12 months, with US-wide retailer distribution and 67% single-year gain. Rapid launch and commercialization after recruitment under $100M PIPE. Created a comprehensive commercialization plan encompassing manufacturing, distribution, managed care, trade, and sales – including the rapid recruitment and onboarding of 375 field sales representatives. Built out the leadership team to recruit top tier investor relations, finance, legal, sales, operations, and human resources talent. Held full P&L responsibility; oversaw 10 direct and ~400 indirect reports across finance, R&D, business development, manufacturing, sales & marketing, investor and public relations, etc.• Prescriber Adoption: Generated 200,000+ prescriptions from 16,000+ prescribers—producing $130M revenue potential.• Achieved Tier 3, zero-restriction Medicaid status among 90% of pharmacy and managed care organizations.• Broad Distribution: Achieved nationwide retail distribution despite low-volume forecasts — leveraging executive-level contacts at major chains and wholesalers. Brought in McKesson, Cardinal, AmerisourceBergen, Walmart, and other retailers.• Strong Results: Built and executed an award-winning targeted marketing campaign yielding first-year sales of $14.8M.

Achieved transformative industry impact with unprecedented product launch and sales strategies. Led groundbreaking product commercialization success, marketing, product adoption, and promotional strategies, driving profitable prescription pipeline forecasted to deliver $500M over 5 years. Achieved #1 Physician / Pharmacist-recommended status for 2 consecutive years for Mucinex, placing product among fastest to achieve launch-to-recommended rankings industry-wide. Conferred with and built strong relationships among stakeholders, suppliers, teams, and industry authorities.• Sales & Marketing Success: Secured $100M MUCINEX sales run rate via Rx promotional strategy for OTC product; proceeds funded a $22M TV campaign that further drove sales and tripled brand recognition. Carved unique market position with pricing and tablet-count strategies, plus generating $30M+ in government sales via 500-count offering.• Industry Recognition: Won DIANA Awards at Healthcare Distribution Management Association (HDMA) Leadership Forum, taking honors in Best New OTC Product Introduction (Mucinex DM), Best New Pharmaceutical Product Introduction and/or Product Promotion (Mucinex for Children), and others.• Multiple Product Rollouts: Oversaw launch for 13 products (Mucinex D, Mucinex DM, Mucinex for Children, Mucinex Nasal Sprays, Grape Delsym, and others), with key role in D/DM marketing strategies.Led M&A strategy resulting in Delsym acquisition, plus business development techniques generating 84% improvement in 2 years. Expanded sales force to high-performing, 125-member national team.• Distribution Leadership: Preserved company reputation by quickly resolving $30M backorder issues; doubled capacity with manufacturing operation purchase from Cardinal Health; cut COGS 30% with materials sourcing to Taiwan.• Post-M&A Authority: Selected by Reckitt Benckiser PLC as sole executive chartered with continuing sales momentum during post-buyout period.

Gained pharma knowledge and insights at world-leading supplier of market intelligence to the pharmaceutical and healthcare industries, setting the stage to implement strategies that would generate billions in revenue for multiple Rx brands. Salesperson of the Year; served as sole rep closing Market Research / Sales Management Service deals.